2011: Foundation of Katairo with the main purpose of developing its lead compound Remofuscin for the treatment of Stargardt disease
2013: Orphan drug designation for Remofuscin for the treatment of Stargardt disease in the EU.
2017: Licensing of extensive data and relevant IP rights from the original developer of Katairo's lead compound
2017: EU funding for a phase 2 clinical proof-of-concept trial in Stargardt together with a European consortium.
2017: Orphan drug designation for Remofuscin for the treatment of Stargardt disease in the USA.
2019: Approval of phase 2 clinical proof-of-concept trial in several European countries and start of enrolment.
